Viewing Study NCT02938520

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:23 AM
Ignite Modification Date: 2026-03-05 @ 6:01 AM
Study NCT ID: NCT02938520
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-03-21
First Post: 2016-09-15
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Sponsor: ViiV Healthcare
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HIV Infections View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Antiretroviral agent View
None Maintenance View
None rilpivirine View
None dolutegravir View
None TMC278 View
None Triumeq View
None non-nucleoside reverse transcriptase inhibitor View
None once monthly, every 4 weeks, once daily View
None GSK1265744 View
None CAB View
None Tivicay View
None Long-Acting Intramuscular rilpivirine View
None lamivudine View
None integrase inhibitor View
None Long-Acting Intramuscular Cabotegravir View
None ART naïve View
None cabotegravir View
None abacavir View